Cargando…
A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART(®)) protein in patients with relapsed/refractory metastatic colorectal carcinoma
Autores principales: | Hurwitz, Herbert, Crocenzi, Todd, Lohr, Joanna, Bonvini, Ezio, Johnson, Syd, Moore, Paul, Wigginton, Jon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288761/ http://dx.doi.org/10.1186/2051-1426-2-S3-P86 |
Ejemplares similares
-
A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML)
por: Uy, Geoffrey, et al.
Publicado: (2014) -
Mouse Genome Database (MGD): Knowledgebase for mouse–human comparative biology
por: Blake, Judith A, et al.
Publicado: (2020) -
Mouse Genome Database (MGD) 2019
por: Bult, Carol J, et al.
Publicado: (2019) -
The Mouse Genome Database (MGD): updates and enhancements
por: Blake, Judith A., et al.
Publicado: (2006) -
Preoperative Management of MGD Alleviates the Aggravation of MGD and Dry Eye Induced by Cataract Surgery: A Prospective, Randomized Clinical Trial
por: Song, Peng, et al.
Publicado: (2019)